 | Up a level |
Journal Article
Broeckelmann, Paul J., McMullen, Suzanne, Ben Wilson, J., Mueller, Kerstin, Goring, Sarah, Stamatoullas, Aspasia, Zagadailov, Erin, Gautam, Ashish, Huebner, Dirk, Dalal, Mehul and Illidge, Tim (2019). Patient and physician preferences for first-line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom. Br. J. Haematol., 184 (2). S. 202 - 215. HOBOKEN: WILEY. ISSN 1365-2141
Broeckelmann, Paul J., Zagadailov, Erin A., Corman, Shelby L., Chirikov, Viktor, Johnson, Courtney, Macahilig, Cynthia, Seal, Brian, Dalal, Mehul R. and Illidge, Tim (2017). Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study. Eur. J. Haematol., 99 (6). S. 553 - 559. HOBOKEN: WILEY. ISSN 1600-0609
Galluzzi, Lorenzo, Vitale, Ilio, Warren, Sarah, Adjemian, Sandy, Agostinis, Patrizia 
ORCID: 0000-0003-1314-2115, Buque Martinez, Aitziber, Chan, Timothy A., Coukos, George, Demaria, Sandra ORCID: 0000-0003-4426-0499, Deutsch, Eric, Draganov, Dobrin, Edelson, Richard L., Formenti, Silvia C., Fucikova, Jitka, Gabriele, Lucia, Gaipl, Udo S., Gameiro, Sofia R., Garg, Abhishek D., Golden, Encouse, Han, Jian, Harrington, Kevin J., Hemminki, Akseli, Hodge, James W., Hossain, Dewan Md Sakib, Illidge, Tim ORCID: 0000-0003-3191-7324, Karin, Michael, Kaufman, Howard L., Kepp, Oliver ORCID: 0000-0002-6081-9558, Kroemer, Guido, Lasarte, Juan Jose, Loi, Sherene, Lotze, Michael T., Manic, Gwenola, Merghoub, Taha, Melcher, Alan A., Mossman, Karen L., Prosper, Felipe ORCID: 0000-0001-6115-8790, Rekdal, Oystein, Rescigno, Maria ORCID: 0000-0002-6464-509X, Riganti, Chiara, Sistigu, Antonella, Smyth, Mark J., Spisek, Radek, Stagg, John, Strauss, Bryan E., Tang, Daolin, Tatsuno, Kazuki, van Gool, Stefaan W., Vandenabeele, Peter, Yamazaki, Takahiro, Zamarin, Dmitriy, Zitvogel, Laurence, Cesano, Alessandra and Marincola, Francesco M.
(2020).
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death.
J. Immunother. Cancer, 8 (1).
LONDON:
BMJ PUBLISHING GROUP.
ISSN 2051-1426
Karuturi, Meghan S., Arai, Sally, Chen, Robert W., Gopal, Ajay K., Feng, Lei, Yuan, Ying, Smith, Scott E., Ansell, Stephen M., Rosenblatt, Joseph D., Savage, Kerry J., Ramchandren, Radhakrishnan, Bartlet, Nancy L., Cheson, Bruce D., Forero-Torres, Andres, Moskowitz, Craig H., Connors, Joseph M., Fanale, Michelle A., de Vos, Sven, Engert, Andreas, Illidge, Tim, Borchmann, Peter, Morschhauser, Franck, Horning, Sandra J. and Younes, Anas (2012). Overall Survival Benefit for Patients with Relapsed Hodgkin Lymphoma Treated with Brentuximab Vedotin After Autologous Stem Cell Transplant. Blood, 120 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 0006-4971
Zagadailov, Erin A., Corman, Shelby, Chirikov, Viktor, Johnson, Courtney, Macahilig, Cynthia, Seal, Brian, Dalal, Mehul R., Broeckelmann, Paul J. and Illidge, Tim (2018). Real-world effectiveness of brentuximab vedotin versus physicians' choice chemotherapy in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and Germany. Leuk. Lymphoma, 59 (6). S. 1413 - 1420. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403